Dapirolizumab, a newly developed anti-CD40L antibody, showed a trend to ameliorate disease activity, such as hematuria, proteinuria, complement and dsDNA antibody levels.
← all excerpts
A Novel Long Noncoding RNA lincRNA00892 Activates CD4<sup>+</sup> T Cells in Systemic Lupus Erythematosus by Regulating CD40L.
1
—
—